ArticleBMC gastroenterology2025
Sodium butyrate entrapped chitosan-PAMAM for suppression of colorectal cancer cells.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lung cancer therapy using a chitosan-based nano drug discovery system of silver nanoparticles and chemotherapeutics.Discover oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCancer treatment is a major concern of health worldwide. Nowadays, colorectal cancer is one of the most prevalent diseases throughout the globe. Therefore, novel cancer treatment modalities are required to stop cancer. Thus, this paper aims to develop a novel drug delivery system (DDS) based on Chitosan (CS), polyamidoamine (PAMAM G4), and Nanoparticles (NP) for efficient delivery of sodium butyrate (NB) and Fe2O3 to SW480 colorectal cancer cells.
methodsTo do so, after characterizing the nanocarrier with FT-IR, DLS, TEM, and TGA, nanometric size (40-65 nm), high drug content (23% Fe2O3 and 3% NB), controlled NB release (4% within 2 h), and pH-sensitive NB release (35% within 2 h) were measured for CS-PAMAM-Fe2O3-NB.
resultIn biomedical tests, MTT assay indicated 10% (after 24 h), 8% (after 48 h), and 7% (after 72 h) cell viabilities for 200 nM concentration of CS-PAMAM-Fe2O3-NB nanocarrier on SW480 cells while pure NB did not have potential toxicity on cancer cells. IC50 determined for 25 nM after 24 h. qRT-PCR test indicated a 7-fold and 10-fold increase for Caspase9 and Bax apoptotic genes whereas 0.3-fold expression quantified for Bcl2 anti-apoptotic gene.
conclusionAccording to the obtained results, it can be concluded that the fabricated nanocarrier would be a potential DDS against colorectal cancer cells. The results of these biomedical tests have approved potential the ability of the synthesized DDS in the inhibition of colorectal cancer cells. High biocompatibility was shown in MSC normal cells which further verified the efficiency of CS-PAMAM-Fe2O3-NB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.